title: [Atherosclerosis and vascular calcification in hemodialysis patients].
abstract: Cardiovascular disease is the largest cause of mortality in hemodialysis patients. Cardiovascular mortality is fivefold to twentyfold higher in hemodialysis patients than in the general population. Atherosclerosis and vascular calcification are the characteristic complications in hemodialysis patients. Hemodialysis patients have traditional risk factors such as abnormal lipid metabolism and uremia-related risk factors such as oxidative stress and hyperphosphatemia. Oxidative stress takes place by increased production of oxidants by leukocytes and antioxidant loss of vitamin C and E. Oxidatively modified LDL exist in the circulation by excess of oxidative stress in hemodialysis patients. Oxidative stress is a major contributor to accelerated development atherosclerosis. Oxidative stress and hyperphosphatemia also influence vascular calcification. The pattern of vascular calcification in hemodialysis patient is characterized by mineral deposition in the tunica media. It is reported that the obvious calcification in aorta and artery of the MGP knockout mouse is recognized. It is indicated that MGP has the inhibitory effect of the calcification of vessel wall. Vitamin E protects atherosclerosis and vascular calcification in hemodialysis patients. It is also important to control hyperphosphatemia for vascular calcification.
authors.affiliation: Department of Internal Medicine III, Wakayama Medical University.
authors.forename: Naohisa
authors.initials: N
authors.lastname: Hirasaka
authors.forename: Xiang-Ming
authors.initials: XM
authors.lastname: Liang
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Mune
mesh_terms: D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology* / Q000517:prevention & control; D002114:Calcinosis / Q000209:etiology* / Q000517:prevention & control; D002135:Calcium-Binding Proteins / Q000502:physiology / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control; D002423:Cause of Death; D016326:Extracellular Matrix Proteins / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D050356:Lipid Metabolism; D008659:Metabolic Diseases / Q000150:complications; D051379:Mice; D018384:Oxidative Stress / Q000502:physiology; D010758:Phosphorus / Q000097:blood; D010760:Phosphorus Metabolism Disorders / Q000150:complications; D006435:Renal Dialysis / Q000009:adverse effects* / Q000401:mortality; D012307:Risk Factors; D014511:Uremia / Q000150:complications; D014810:Vitamin E / Q000627:therapeutic use; D000097568:Matrix Gla Protein
chemical_list: D002135:Calcium-Binding Proteins; D016326:Extracellular Matrix Proteins; D010758:Phosphorus; D014810:Vitamin E; D000097568:Matrix Gla Protein